An oral pharmaceutical composition containing oseltamivir phosphate and its application
By preparing an oral immediate-release film containing oseltamivir phosphate, the problems of frequent administration and poor compliance in existing technologies have been solved, achieving rapid dissolution and high bioavailability, enhancing the antiviral treatment effect, and making it suitable for patients with dysphagia.
Patent Information
- Application Number
- CN202411528683.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-30
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2044-10-30
AI Technical Summary
Existing conventional oral formulations of oseltamivir phosphate, such as capsules and granules, suffer from problems such as frequent administration and poor patient compliance, and are particularly unsuitable for patients with swallowing difficulties. Furthermore, there is a lack of oral immediate-release film formulation technology for oseltamivir phosphate.
To develop an oral immediate-release film containing oseltamivir phosphate, the composition comprising oseltamivir phosphate, superoxide dismutase, quercetin and tetrahydromethylpyrimidine carboxylic acid, and to prepare the film-forming agent by a specific preparation method, utilizing sublingual mucosal absorption to avoid the first-pass effect of the liver and improve bioavailability.
It achieves rapid dissolution, improves bioavailability, enhances anti-influenza virus efficacy, reduces side effects, improves patient compliance, and has antioxidant, anti-inflammatory, and multi-target intervention therapeutic effects.
Smart Images

Figure BDA0005109932240000061 
Figure BDA0005109932240000071 
Figure BDA0005109932240000081
Abstract
Description
Technical Field
[0001] This invention relates to the field of pharmaceutical formulation technology, and in particular to an oral pharmaceutical composition containing oseltamivir phosphate and its application. Background Technology
[0002] Oseltamivir phosphate is a drug used to treat influenza virus infections, effectively treating both influenza A and B. Oseltamivir phosphate is a neuraminidase inhibitor that blocks viral replication and reproduction within host cells by inhibiting the neuraminidase activity of the influenza virus. It primarily targets the neuraminidase of the influenza virus, thereby reducing viral replication, shortening the duration of illness, and reducing viral transmission within the host.
[0003] Currently, conventional oral formulations of oseltamivir phosphate, such as capsules, granules, and tablets, all suffer from problems such as frequent administration and poor patient compliance. Therefore, developing a novel oseltamivir phosphate dosage form and applying it to the clinical treatment of influenza virus is of practical significance.
[0004] Film-based medications are particularly suitable for bedridden patients with swallowing difficulties, the elderly, and children due to their simple preparation methods, portability, lack of need for water or chewing, rapid onset of action, and high patient compliance. Because the sublingual mucosa is rich in veins, drugs are directly absorbed into the bloodstream, thus avoiding the first-pass effect of the liver and improving drug bioavailability. Therefore, film-based medications, as a novel type of immediate-release solid dosage form, have attracted the attention and application of the pharmaceutical industry.
[0005] Currently, many patents disclose technical solutions for oral fast-release films, but the technical solutions are not entirely the same, and the final effects are also not entirely the same. Furthermore, there is no technical solution specifically for oral fast-release films containing oseltamivir phosphate. Summary of the Invention
[0006] In view of this, the present invention proposes an oral pharmaceutical composition containing oseltamivir phosphate and its application.
[0007] The technical solution of this invention is implemented as follows:
[0008] An oral pharmaceutical composition containing oseltamivir phosphate, comprising, by weight, the following ingredients: 20-40 parts oseltamivir phosphate, 8-10 parts superoxide dismutase, 3-5 parts quercetin, and 0.8-1.2 parts tetrahydromethylpyrimidine carboxylic acid.
[0009] Furthermore, it includes the following ingredients: 30 parts oseltamivir phosphate, 9 parts superoxide dismutase, 4 parts quercetin, and 1 part tetrahydromethylpyrimidine carboxylic acid.
[0010] Application of oral pharmaceutical compositions containing oseltamivir phosphate in the preparation of antiviral drugs for influenza.
[0011] Furthermore, the dosage form of the anti-influenza virus drug is an oral immediate-release film.
[0012] Furthermore, the oral immediate-release film comprises, by weight, the following raw materials: 20-40 parts oseltamivir phosphate, 8-10 parts superoxide dismutase, 3-5 parts quercetin, 0.8-1.2 parts tetrahydromethylpyrimidine carboxylic acid, 15-20 parts hydroxypropyl methylcellulose, 1-3 parts xanthan gum, and 5-7 parts flavoring agent.
[0013] Furthermore, the preparation method of the oral immediate-release film specifically includes:
[0014] (1) Pulverize oseltamivir phosphate and control the particle size to 80-90 μm;
[0015] (2) Add the pulverized oseltamivir phosphate, superoxide dismutase and quercetin to phosphate-sodium phosphate buffer, stir well to obtain the drug solution;
[0016] (3) Add hydroxypropyl methylcellulose and xanthan gum to water and stir until homogeneous to obtain hydroxypropyl methylcellulose-xanthan gum solution;
[0017] (4) Add the drug solution to the hydroxypropyl methylcellulose-xanthan gum solution, stir ultrasonically, add tetrahydromethylpyrimidine carboxylic acid and flavoring agent, continue stirring to obtain film-forming drug solution, degas, coat film, cut to obtain target oral immediate release film.
[0018] Furthermore, in step (2), the pH of the phosphate-sodium phosphate buffer is 7.2-7.4, and the concentration is 0.01-0.02 mol / L; the solid-liquid ratio of the pulverized oseltamivir phosphate, superoxide dismutase and quercetin to the phosphate-sodium phosphate buffer is 1:3-5 mg / mL.
[0019] Furthermore, in step (3), the concentration of the hydroxypropyl methylcellulose-xanthan gum solution is 1%-3% w / v.
[0020] Furthermore, in step (4), the volume ratio of the drug solution to the hydroxypropyl methylcellulose-xanthan gum solution is 1:2-4.
[0021] Furthermore, in step (4), the ultrasonic stirring is performed at 20-30 kHz and 40-50 ℃ for 5-15 min; the stirring time is 30-40 min.
[0022] Compared with the prior art, the beneficial effects of the present invention are:
[0023] 1. The oral immediate-release film prepared by this invention can dissolve rapidly, avoid the first-pass effect of the liver, improve bioavailability, achieve a higher local drug concentration, quickly relieve symptoms, enhance the efficacy of anti-influenza virus drugs, have good palatability, are convenient for patients to take, improve compliance, and reduce side effects.
[0024] 2. Oseltamivir phosphate, as the main anti-influenza virus component of this invention, combined with superoxide dismutase, can reduce oxidative stress caused by viral infection, decrease cell damage, and improve the overall anti-influenza virus treatment effect through multi-target intervention; tetrahydromethylpyrimidine carboxylic acid serves as a drug stabilizer; quercetin is a natural plant flavonoid with multiple functions including antioxidant, anti-inflammatory, and antiviral. The addition of quercetin not only acts as an antioxidant but also has anti-inflammatory properties that can alleviate local inflammation caused by influenza virus and enhance the immune response. Detailed Implementation
[0025] To better understand the technical content of this invention, specific embodiments are provided below to further illustrate the invention.
[0026] Unless otherwise specified, the experimental methods used in the embodiments of this invention are all conventional methods.
[0027] Unless otherwise specified, all materials and reagents used in the embodiments of this invention are commercially available.
[0028] The superoxide dismutase of this invention was purchased from Jiangsu Caiwei Biotechnology Co., Ltd.
[0029] The quercetin used in this invention was purchased from Xi'an Fenghe Biotechnology Co., Ltd.
[0030] The flavoring agent of this invention is one of sucralose, sweet orange flavoring, or sucrose.
[0031] Example 1
[0032] An oral pharmaceutical composition containing oseltamivir phosphate, comprising, by weight, the following ingredients: 30 parts oseltamivir phosphate, 9 parts superoxide dismutase, 4 parts quercetin, and 1 part tetrahydromethylpyrimidine carboxylic acid.
[0033] The oral immediate-release film of this embodiment comprises the following raw materials in parts by weight: 30 parts oseltamivir phosphate, 9 parts superoxide dismutase, 4 parts quercetin, 1 part tetrahydromethylpyrimidine carboxylic acid, 18 parts hydroxypropyl methylcellulose, 2 parts xanthan gum, and 6 parts flavoring agent.
[0034] The preparation method of the oral immediate-release film in this embodiment:
[0035] (1) Pulverize oseltamivir phosphate and control the particle size to 85±5μm;
[0036] (2) According to the solid-liquid ratio of 1:4 mg / mL, add the pulverized oseltamivir phosphate, superoxide dismutase and quercetin to a 0.01 mol / L phosphate-sodium phosphate buffer (pH = 7.3 ± 0.1), stir well to obtain the drug solution;
[0037] (3) Add hydroxypropyl methylcellulose and xanthan gum to water and stir evenly to obtain a 2% w / v hydroxypropyl methylcellulose-xanthan gum solution;
[0038] (4) Add the drug solution to the hydroxypropyl methylcellulose-xanthan gum solution at a volume ratio of 1:3, and ultrasonically stir at 25 kHz and 45 ℃ for 10 min. Add tetrahydromethylpyrimidine carboxylic acid and flavoring agent, and continue stirring for 35 min to obtain film-forming drug solution. Degas, coat the film, and cut to obtain the target oral immediate-release film.
[0039] Example 2
[0040] An oral pharmaceutical composition containing oseltamivir phosphate, comprising, by weight, the following ingredients: 20 parts oseltamivir phosphate, 8 parts superoxide dismutase, 3 parts quercetin, and 0.8 parts tetrahydromethylpyrimidine carboxylic acid.
[0041] The oral immediate-release film of this embodiment comprises the following raw materials in parts by weight: 20 parts oseltamivir phosphate, 8 parts superoxide dismutase, 3 parts quercetin, 0.8 parts tetrahydromethylpyrimidine carboxylic acid, 15 parts hydroxypropyl methylcellulose, 1 part xanthan gum, and 5 parts flavoring agent.
[0042] The preparation method of the oral immediate-release film in this embodiment:
[0043] (1) Pulverize oseltamivir phosphate and control the particle size to 85±5μm;
[0044] (2) According to the solid-liquid ratio of 1:3 mg / mL, add the pulverized oseltamivir phosphate, superoxide dismutase and quercetin to a 0.01 mol / L phosphate-sodium phosphate buffer (pH = 7.3 ± 0.1), stir well to obtain the drug solution;
[0045] (3) Add hydroxypropyl methylcellulose and xanthan gum to water and stir evenly to obtain a hydroxypropyl methylcellulose-xanthan gum solution with a concentration of 1% w / v.
[0046] (4) Add the drug solution to the hydroxypropyl methylcellulose-xanthan gum solution at a volume ratio of 1:2, and stir ultrasonically at 20kHz and 40℃ for 5 minutes. Add tetrahydromethylpyrimidine carboxylic acid and flavoring agent, and continue stirring for 30 minutes to obtain film-forming drug solution. Degas, coat the film, and cut to obtain the target oral immediate-release film.
[0047] Example 3
[0048] An oral pharmaceutical composition containing oseltamivir phosphate, comprising, by weight, the following ingredients: 40 parts oseltamivir phosphate, 10 parts superoxide dismutase, 5 parts quercetin, and 1.2 parts tetrahydromethylpyrimidine carboxylic acid.
[0049] The oral immediate-release film of this embodiment comprises the following raw materials in parts by weight: 40 parts oseltamivir phosphate, 10 parts superoxide dismutase, 5 parts quercetin, 1.2 parts tetrahydromethylpyrimidine carboxylic acid, 20 parts hydroxypropyl methylcellulose, 3 parts xanthan gum, and 7 parts flavoring agent.
[0050] The preparation method of the oral immediate-release film in this embodiment:
[0051] (1) Pulverize oseltamivir phosphate and control the particle size to 85±5μm;
[0052] (2) According to the solid-liquid ratio of 1:5 mg / mL, add the pulverized oseltamivir phosphate, superoxide dismutase and quercetin to a 0.02 mol / L phosphate-sodium phosphate buffer (pH = 7.3 ± 0.1), stir well to obtain the drug solution;
[0053] (3) Add hydroxypropyl methylcellulose and xanthan gum to water and stir evenly to obtain a hydroxypropyl methylcellulose-xanthan gum solution with a concentration of 3% w / v.
[0054] (4) Add the drug solution to the hydroxypropyl methylcellulose-xanthan gum solution at a volume ratio of 1:4, and stir ultrasonically at 30 kHz and 50 ℃ for 15 min. Add tetrahydromethylpyrimidine carboxylic acid and flavoring agent, and continue stirring for 40 min to obtain film-forming drug solution. Degas, coat the film, and cut to obtain the target oral immediate-release film.
[0055] Comparative Example 1
[0056] The difference from Example 1 is that the oral pharmaceutical composition containing oseltamivir phosphate is prepared as a granule formulation, otherwise it is the same as Example 1.
[0057] The preparation method of the oseltamivir phosphate granule formulation in this comparative example is as follows:
[0058] (1) Pulverize oseltamivir phosphate and control the particle size to 85±5μm;
[0059] (2) According to the solid-liquid ratio of 1:4 mg / mL, add the pulverized oseltamivir phosphate, superoxide dismutase and quercetin to a 0.01 mol / L phosphate-sodium phosphate buffer (pH = 7.3 ± 0.1), stir well to obtain the drug solution;
[0060] (3) Add the drug solution to a 5wt% microcrystalline cellulose solution at a volume ratio of 1:4, add flavoring agent and stir, spray dry to obtain granules, dry, sieve, coat to obtain the target oseltamivir phosphate granule formulation.
[0061] Comparative Example 2
[0062] The difference from Example 1 is that the oral pharmaceutical composition containing oseltamivir phosphate is prepared into a capsule formulation, otherwise it is the same as Example 1.
[0063] The oseltamivir phosphate capsule formulation of this comparative example comprises the following ingredients by weight: 30 parts oseltamivir phosphate, 9 parts superoxide dismutase, 4 parts quercetin, 1 part tetrahydromethylpyrimidine carboxylic acid, 4 parts pregelatinized starch, 2 parts sodium stearate, 6 parts povidone K30, and 6 parts flavoring agent.
[0064] The preparation method of the oseltamivir phosphate capsule formulation in this comparative example is as follows:
[0065] (1) Pulverize oseltamivir phosphate and control the particle size to 85±5μm;
[0066] (2) The pulverized oseltamivir phosphate, superoxide dismutase, quercetin, pregelatinized starch, sodium stearate and flavoring agent are mixed and dispersed in a 5 wt% microcrystalline cellulose solution at a solid-liquid ratio of 1:4 mg / mL. Tetrahydromethylpyrimidine carboxylic acid is added, the mixture is stirred and dispersed, wet granulated and dried to obtain the premix.
[0067] (3) Add povidone K30 to the premix, mix, and fill into soft capsule shells to obtain the target oseltamivir phosphate capsule formulation.
[0068] Experimental Example 1
[0069] Dissolution tests were conducted on the oseltamivir phosphate formulations prepared in Examples 1-3 and Comparative Examples 1-2 of this invention, as well as commercially available oseltamivir phosphate granules (Tamiflu) and commercially available oseltamivir phosphate capsules (Tamiflu).
[0070] Experimental Methods: The in vitro dissolution rate of the oral immediate-release film formulation was determined according to Method IV of General Chapter IV of the 2015 edition of the Chinese Pharmacopoeia. Using ultrasonically degassed PBS (pH = 6.8) as the release medium at a temperature of 37 ± 0.5℃, a 2.5*3cm film was fixed in the center of two discs. The mesh disc was then placed under the dissolution vessel, parallel to the rotating surface of the paddle, at a distance of 25 ± 2 mm. At a rotation speed of 50 r / min, 5 ml of the release solution was collected at 0.5 min, 1 min, 1.5 min, 2 min, 3 min, 4 min, 6 min, 10 min, 15 min, 30 min, and 60 min, and an equal volume of blank release medium at the same temperature was added. After filtration through a microporous membrane, the filtrate was subjected to HPLC analysis. Granule and capsule formulations were determined according to their respective in vitro dissolution methods. The data results are shown in Table 1.
[0071] Table 1
[0072]
[0073]
[0074] As can be seen from Table 1, the oseltamivir phosphate oral immediate-release film prepared in Examples 1-3 of the present invention can dissolve rapidly, and has a faster release rate than Comparative Example 1 (granules) and Comparative Example 2 (capsules), and is superior to commercially available oseltamivir phosphate granules and commercially available oseltamivir phosphate capsules.
[0075] Comparative Example 3
[0076] The difference from Example 1 is that superoxide dismutase is missing, and the missing components are allocated according to the ratio of oseltamivir phosphate to quercetin. Otherwise, it is the same as Example 1.
[0077] The oral pharmaceutical composition containing oseltamivir phosphate in this comparative example comprises, by weight, the following ingredients: 37.9 parts oseltamivir phosphate, 5.1 parts quercetin, and 1 part tetrahydromethylpyrimidine carboxylic acid.
[0078] Comparative Example 4
[0079] The difference from Example 1 is that quercetin is missing, and the missing components are allocated according to the ratio of oseltamivir phosphate to superoxide dismutase. Otherwise, it is the same as Example 1.
[0080] The oral pharmaceutical composition containing oseltamivir phosphate in this comparative example comprises, by weight, the following ingredients: 33.1 parts oseltamivir phosphate, 9.9 parts superoxide dismutase, and 1 part tetrahydromethylpyrimidine carboxylic acid.
[0081] Experimental Example 2
[0082] In vivo pharmacokinetic experiments
[0083] 1. Experimental subjects: 110 female SD mice (weight 20±5g).
[0084] 2. Influenza virus: A / PR8 / 8 / 34(H1N1)(PR8), Source: Guangzhou Institute of Respiratory Diseases.
[0085] 2. Viral infection method: Dilute PR8 virus to 200 pfu / 40 μL (2 MLD) with PBS. 50 After mice were anesthetized with isoflurane, 40 μL of diluted PR8 virus was aspirated with a 100 μL pipette and dripped into the nasal cavity of the mice through both nostrils.
[0086] 3. Experimental grouping: 110 mice were divided into normal group, virus interference group, Examples 1-3, Comparative Examples 1-4, commercially available oseltamivir phosphate granules and commercially available oseltamivir phosphate capsules, with 10 mice in each group.
[0087] 4. Administration method:
[0088] Normal group: neither infected with the virus nor given medication;
[0089] Virus interference group: Infected with the virus but not given medication;
[0090] Examples 1-3 and Comparative Examples 1-4: The drugs prepared in Examples 1-3 and Comparative Examples 1-4 were first administered 4 hours before viral infection. The drug dosage form was oral immediate-release film administered sublingually to mice, while the granule and capsule dosage forms were administered by gavage. The dose was 2 mg based on oseltamivir phosphate, and administration was continued at 12-hour intervals.
[0091] Commercially available oseltamivir phosphate granules and commercially available oseltamivir phosphate capsules: administered by gavage, first dose 4 hours before viral infection, dose of 2 mg based on oseltamivir phosphate, followed by administration at 12-hour intervals.
[0092] During the period, the mortality of mice was observed, and the survival rate of mice after 10 days was calculated. The results are shown in Table 2.
[0093] Table 2
[0094]
[0095]
[0096] As shown in Table 2, all mice in the normal group survived, while all mice in the virus interference group died, indicating successful model establishment. Compared with the virus interference group, the survival rate of Examples 1-3 was 100%, indicating that the oral immediate-release film of Examples 1-3 has a good anti-influenza virus effect, superior to the commercially available group. The decreased survival rate of Comparative Examples 3-4 indicates that the combined use of oseltamivir phosphate with superoxide dismutase and quercetin has a synergistic effect, enhancing the anti-influenza virus effect.
[0097] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention.
Claims
1. An oral pharmaceutical composition containing oseltamivir phosphate, characterized in that, The ingredients, by weight, include the following: 20-40 parts oseltamivir phosphate, 8-10 parts superoxide dismutase, 3-5 parts quercetin, and 0.8-1.2 parts tetrahydromethylpyrimidine carboxylic acid.
2. The oral pharmaceutical composition containing oseltamivir phosphate as described in claim 1, characterized in that, The ingredients include: 30 parts oseltamivir phosphate, 9 parts superoxide dismutase, 4 parts quercetin and 1 part tetrahydromethylpyrimidine carboxylic acid.
3. The use of the oral pharmaceutical composition containing oseltamivir phosphate according to claim 1 in the preparation of an antiviral drug for influenza, characterized in that, The antiviral drug is in the form of an oral immediate-release film. The preparation method of the oral immediate-release film specifically includes: (1) Pulverize oseltamivir phosphate and control the particle size to 80-90 μm; (2) Add the pulverized oseltamivir phosphate, superoxide dismutase and quercetin to phosphate-sodium phosphate buffer, stir well to obtain the drug solution; (3) Add hydroxypropyl methylcellulose and xanthan gum to water and stir until homogeneous to obtain a hydroxypropyl methylcellulose-xanthan gum solution; (4) Add the drug solution to the hydroxypropyl methylcellulose-xanthan gum solution, stir ultrasonically, add tetrahydromethylpyrimidine carboxylic acid and flavoring agent, continue stirring to obtain film-forming drug solution, degas, coat film, cut to obtain target oral immediate release film.
4. The application as described in claim 3, characterized in that, The oral immediate-release film comprises, by weight, the following ingredients: 20-40 parts oseltamivir phosphate, 8-10 parts superoxide dismutase, 3-5 parts quercetin, 0.8-1.2 parts tetrahydromethylpyrimidine carboxylic acid, 15-20 parts hydroxypropyl methylcellulose, 1-3 parts xanthan gum, and 5-7 parts flavoring agent.
5. The application as described in claim 3, characterized in that, In step (2) of the preparation method of the oral immediate-release film, the pH of the phosphate-sodium phosphate buffer is 7.2-7.4 and the concentration is 0.01-0.02 mol / L; the solid-liquid ratio of the pulverized oseltamivir phosphate, superoxide dismutase and quercetin to the phosphate-sodium phosphate buffer is 1:3-5 mg / mL.
6. The application as described in claim 3, characterized in that, In step (3) of the preparation method of oral instant-release film, the concentration of the hydroxypropyl methylcellulose-xanthan gum solution is 1%-3% w / v.
7. The application as described in claim 3, characterized in that, In step (4) of the preparation method of oral instant-release film, the volume ratio of the drug solution to the hydroxypropyl methylcellulose-xanthan gum solution is 1:2-4.
8. The application as described in claim 3, characterized in that, In step (4) of the preparation method of oral immediate-release film, the ultrasonic stirring is performed at 20-30 kHz and 40-50 ℃ for 5-15 min; the stirring time is 30-40 min.
Citation Information
Patent Citations
Oseltamivir phosphate oral soluble film agent and preparation method thereof
CN115400098A
